Thursday, October 18, 2012
Publication and contact
Computational analysis of
breast cancer samples from patients suggests therapeutic strategies used to
treat ovarian cancer could help treat a class of basal-like breast tumors.
Computational analysis of genomic and proteomic data from primary breast
cancer samples identified basal-like breast tumors as a class with features
similar to those of serous ovarian cancer. The data suggest patients with
this class of breast tumors might benefit from treatment with poly(ADP-ribose)polymerase
inhibitors and/or platinum compounds used to treat serous ovarian cancer.
Next steps could include clinical trials.
Abbott Laboratories has the
PARP inhibitor veliparib in
Phase I and Phase II trials to treat multiple types of cancer.
plc has the PARP inhibitor Olaparib
in Phase I testing to treat brain cancer and Phase II trials to treat solid
Pharmaceutical Inc. has BMN-673
in Phase I/II trials to treat hematologic malignancies and solid tumors.
Published online Oct. 18, 2012
status not applicable
The Cancer Genome Atlas
Network. Nature; published online Sept. 23, 2012;
Contact: Charles M. Perou, The University of North Carolina
at Chapel Hill, Chapel Hill, N.C.
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]